Emílio Alves Odebrecht
Presidente presso Fundação Odebrecht
Provenienza dei contatti di primo grado di Emílio Alves Odebrecht
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Recepta Biopharma SA
 Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil.
11
| Holding Company | Biotechnology | 11 |
Fundação Odebrecht
 Fundação Odebrecht Miscellaneous Commercial ServicesCommercial Services Fundação Odebrecht focuses on the youth and family development in order to create solutions together with local communities, based on their capabilities and needs. The company was founded by Norberto Odebrecht in 1965 and is headquartered in Salvador, Brazil.
9
| Non-Profit Organization | Miscellaneous Commercial Services | 9 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Emílio Alves Odebrecht tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| Fundação Dom Cabral | College/University | Masters Business Admin | |
| Stanford University | College/University | Undergraduate Degree | |
| OPTHEA LIMITED | Biotechnology | Director/Board Member | |
Novonor SA
 Novonor SA Engineering & ConstructionIndustrial Services Novonor engages in infrastructure and energy solutions. Its services include engineering and construction, industry, development and operation of infrastructure and energy projects, creating integrated and innovative solutions that serve both its clients and its communities. The company was founded in 1981and is headquartered in Salvador, Brazil. | Engineering & Construction | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| University College London | College/University | Doctorate Degree | |
| University of Sao Paulo | College/University | Doctorate Degree | |
Vegenics Pty Ltd.
 Vegenics Pty Ltd. Medical/Nursing ServicesHealth Services Part of Opthea Ltd., Vegenics Pty Ltd. is an Australian company that provides medical research, development, and commercialization of biologic drugs. Vegenics was acquired by Opthea Ltd. on August 14, 2008 for $5.06 million. | Medical/Nursing Services | Corporate Officer/Principal | |
Ludwig Institute for Cancer Research Ltd.
 Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | Medical/Nursing Services | Corporate Officer/Principal | |
Cancer Vaccine Acceleration Co. LLC
 Cancer Vaccine Acceleration Co. LLC Financial ConglomeratesFinance Part of Cancer Research Institute, Cancer Vaccine Acceleration Co. LLC is an alternative investment manager. The company is based in New York, NY. | Financial Conglomerates | Director/Board Member | |
| Insper Institute of Education & Research | College/University | Masters Business Admin | |
| Seramtrix, Inc. | Director/Board Member | ||
| Universidade Católica do Salvador | College/University | Undergraduate Degree | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
| Faculdade de Direito da Universidade de São Paulo | College/University | Undergraduate Degree | |
Biozeus Biopharmaceutical SA
 Biozeus Biopharmaceutical SA Miscellaneous Commercial ServicesCommercial Services Biozeus Biopharmaceutical SA operates as a drug development company. It engages in the identifying early-stage drug candidates from Brazilian research institutions and develop them into new therapies for improving and saving lives, worldwide. The company is headquartered in Rio de Janeiro, Brazil. | Miscellaneous Commercial Services | Director/Board Member | |
iOX Therapeutics Ltd.
 iOX Therapeutics Ltd. BiotechnologyHealth Technology iOX Therapeutics Ltd. provides cancer therapeutics services. The company was founded by Vincenzo Cerundolo in February 2015 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member |
Statistiche
Distribuzione geografica
| Brasile | 8 |
| Stati Uniti | 5 |
| Australia | 3 |
| Regno Unito | 3 |
| Belgio | 2 |
Settori
| Consumer Services | 8 |
| Health Technology | 4 |
| Health Services | 3 |
| Industrial Services | 2 |
| Finance | 2 |
Posizioni
| Director/Board Member | 27 |
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 3 |
| Chairman | 2 |
| Doctorate Degree | 2 |
Contatti più connessi
- Borsa valori
- Insiders
- Emílio Alves Odebrecht
- Connessioni Società
